- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07835048
The OSTIAL Study (Optimization of Stent Placement in Aorto-ostial Lesions) (OSTIAL)
Optimisation du Positionnement Des Stents Dans Les lésions Aorto-ostiales : étude Multicentrique Historico-prospective Avec Phase randomisée Comparant l'Angioplastie Coronaire Avec ou Sans Technique du Floating Ballon Étude OSTIAL (Optimizing Stent In Aorto-Ostial Lesion)
Aorto-ostial coronary lesions present a significant challenge during coronary angioplasty. This is due to the difficulty of precisely identifying the aorto-ostial plane and the frequent instability of the guiding catheter during stent deployment.
Despite the angiographic appearance being deemed optimal, several studies have shown a high rate of suboptimal stent positioning at the ostium when subsequent coronary CT angiography (CCTA) assessment is performed.
This suboptimal positioning may be linked to incomplete ostial coverage, which could increase the risk of in-stent restenosis. It may also be linked to excessive stent protrusion into the aorta, which could compromise future procedures, particularly in the context of transcatheter aortic valve replacement.
The "Floating Balloon" (FB) technique has been developed to improve system stability and to reliably mark the aorto-ostial landing zone (AOLZ). A previous study demonstrated the feasibility and accuracy of this technique.
The aim of the current study is to assess the clinical effectiveness of the Floating Balloon. Although this technique is already in use, no study has yet conducted a systematic assessment of stent positioning using CCTA.
The study utilised a combined retrospective-prospective approach to comprehensively evaluate the incidence of suboptimal stent positioning associated with the Floating Balloon technique. This evaluation was conducted by systematically comparing patient outcomes between those treated with the FB and those treated without the FB. The study employed CCTA as a key tool to assess stent position, ensuring a precise analysis of the data.
To achieve this, it is recommended that follow-up data from patients who have already undergone the FB procedure and had their stent position assessed via CCTA (retrospective component) be analysed, while also enrolling new patients and randomizing them into FB and non-FB groups (prospective component).
Studienübersicht
Status
Detaillierte Beschreibung
In order to address the primary objective (namely, to estimate the rate of stent malpositioning), 97 evaluable subjects are required to achieve a precision (half-width of the 95% confidence interval) of +/-10% (assuming a conservative 50% rate of correct positioning).
As assessments are conducted immediately after the procedure, the investigators do not anticipate a significant number of non-evaluable subjects. The proposal is to enrol N=100 subjects in the FB group, with 50 subjects in the retrospective phase and another 50 in the prospective phase.
In order to address the secondary objective of comparing malpositioning rates between the two groups (with and without FB), patients in the non-FB group should be enrolled at a 1:2 ratio. The justification for this number is based on feasibility. This will provide preliminary data for the non-FB group.
Therefore, given our retrospective cohort of 50 FB subjects with available measurements, the prospective phase will include N=50 + 25-or 75 additional subjects (50 in the FB arm and 25 in the non-FB arm). The analyses will therefore cover a total of 125 subjects (100 with FB and 25 without FB).
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Frank FD DIGNE, PHD
- Telefonnummer: 01 49 33 41 13
- E-Mail: f.digne@ccn.fr
Studieren Sie die Kontaktsicherung
- Name: Karima MOUSSOUNI, CRA
- Telefonnummer: 0679145144
- E-Mail: k.moussouni@ccn.fr
Studienorte
-
-
-
Bois-Bernard, Frankreich
- Hôpital privé Bois Bernard
-
Kontakt:
- Sina POROUCHANI, Dr
- Telefonnummer: 0683575767
- E-Mail: sina.porouchani@gmail.com
-
Clermont-Ferrand, Frankreich
- CHU Clermont-Ferrand
-
Kontakt:
- Géraud SOUTEYRAND, Dr
- Telefonnummer: 0473751410
- E-Mail: gsouteyrand@chu-clermontferrand.fr
-
Creil, Frankreich
- GHPSO Creil
-
Kontakt:
- Salim SB BELGUIDOUM, Dr
- Telefonnummer: 0661332746
- E-Mail: salim_0101@hotmail.fr
-
Massy, Frankreich
- Institut Cardiovasculaire Paris Sud - Massy
-
Kontakt:
- Nicolas Amabile
- Telefonnummer: 0612523423
- E-Mail: nicolasamabile@yahoo.fr
-
Saint-Denis, Frankreich
- Centre cardiologique du nord
-
Kontakt:
- Frank FD DIGNE, PHD
- Telefonnummer: 01 49 33 41 13
- E-Mail: f.digne@ccn.fr
-
Kontakt:
- Karima KM MOUSSOUNI, Cra
- Telefonnummer: 0679145144
-
Unterermittler:
- Arthur AD DARMON, Dr
-
Saint-Etienne, Frankreich
- CHU de saint étienne
-
Kontakt:
- Marouane BOUKHRIS, Dr
- Telefonnummer: 0650278487
- E-Mail: marouaneboukhris1@gmail.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Male or female aged over 18 years
- Prospective part: Patient who has signed an informed consent form
- Retrospective part: No objection to the use of personal data for this research
- Indication for coronary angioplasty for an aorto-ostial lesion (right coronary artery or left main coronary artery) for patients included in the prospective part / Patients in the historical part who underwent coronary angioplasty for an aorto-ostial lesion (right coronary artery or left main coronary artery) using the "floating balloon" (FB) technique, followed by a CCTA assessment of positioning
- Affiliation with or beneficiary of a social security scheme.
Exclusion Criteria:
- Contraindication to coronary CT angiography (severe renal impairment not requiring dialysis (GFR ≤ 30 ml/min)), applicable only to patients included in the prospective part
- Refusal of consent (patients included in the prospective part)
- Objection to the use of personal data (patients in the retrospective part)
- Patient unable to read, write, or understand French
- Vulnerable patient as defined by Article L1121-6 of the Public Health Code (CSP)
- Adult patient placed under guardianship, curatorship, or judicial protection
- Patient unable to personally provide consent pursuant to Article L.1121-8 of the CSP, or an adult under legal protection
- Pregnant or breastfeeding woman as defined by Article L1121-5 of the CSP
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Coronary angioplasty using the floating balloon technique
|
Coronary angioplasty using the FB technique involves the following steps:
|
|
Aktiver Komparator: Coronary angioplasty without the floating-balloon technique
|
Angioplasty of the aorto-ostial lesion without the jailed-balloon (FB) technique will be performed as follows:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
The number of participants in whom stent placement was technically successful and who were evaluated by CT scan.
Zeitfenster: At the end of the procedure
|
At the end of the procedure
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
The secondary outcome is the rate of major adverse cardiovascular events (MACE).
Zeitfenster: 12 months after the surgery procedure
|
The secondary outcome is the rate of major adverse cardiovascular events (MACE), including cardiac mortality, all-cause mortality, myocardial infarction (MI), target lesion revascularization (TLR) and hospitalisation for cardiovascular causes. |
12 months after the surgery procedure
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Frank FD DIGNE, PHD, Centre Cardiologique du Nord
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Dishmon DA, Elhaddi A, Packard K, Gupta V, Fischell TA. High incidence of inaccurate stent placement in the treatment of coronary aorto-ostial disease. J Invasive Cardiol. 2011 Aug;23(8):322-6.
- Digne F, Darmon A, Belguidoum S, Nejjari M, Feignoux J. Optimizing Stent Placement in Ostial Coronary Lesions With the Floating Balloon Technique: The OSTIAL (Optimizing Stent In Aorto-Ostial Lesion) Pivotal Study. Catheter Cardiovasc Interv. 2025 Apr;105(5):1269-1277. doi: 10.1002/ccd.31449. Epub 2025 Feb 17.
- Digne F, Darmon A, Nejjari M. Optimizing Stent Placement in Aorto-Ostial Lesions: Introducing the New Floating Balloon Technique. JACC Cardiovasc Interv. 2024 Sep 9;17(17):2082-2084. doi: 10.1016/j.jcin.2024.06.025. Epub 2024 Aug 21. No abstract available.
- Jaffe R, Halon DA, Shiran A, Rubinshtein R. Percutaneous treatment of aorto-ostial coronary lesions: Current challenges and future directions. Int J Cardiol. 2015;186:61-6. doi: 10.1016/j.ijcard.2015.03.161. Epub 2015 Mar 17.
- Yamamoto K, Sato T, Salem H, Matsumura M, Fall KN, Prasad M, Ng VG, Sethi SS, Nazif TM, Parikh SA, Vahl TP, Ali ZA, Karmpaliotis D, Rabbani LE, Collins MB, Leon MB, McEntegart MB, Moses JW, Kirtane AJ, Mintz GS, Maehara A. Mechanisms and treatment outcomes of ostial right coronary artery in-stent restenosis. EuroIntervention. 2023 Aug 7;19(5):e383-e393. doi: 10.4244/EIJ-D-23-00107.
- Freeman M, Clark DJ, Andrianopoulos N, Duffy SJ, Lim HS, Brennan A, Charter K, Shaw J, Horrigan M, Ajani AE, Sebastian M, Reid CM, Farouque HM; Melbourne Interventional Group. Outcomes after percutaneous coronary intervention of ostial lesions in the era of drug-eluting stents. Catheter Cardiovasc Interv. 2009 May 1;73(6):763-8. doi: 10.1002/ccd.21941.
- Rubinshtein R, Ben-Dov N, Halon DA, Lavi I, Finkelstein A, Lewis BS, Jaffe R. Geographic miss with aorto-ostial coronary stent implantation: insights from high-resolution coronary computed tomography angiography. EuroIntervention. 2015 Jul;11(3):301-7. doi: 10.4244/EIJV11I3A57.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2026-A01154-47
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .